Literature DB >> 31802348

Double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane antibody could predict end-stage renal disease in ANCA-associated vasculitis: a monocentric pilot study.

Byung-Woo Yoo1, Sung Soo Ahn1, Seung Min Jung1, Jason Jungsik Song1,2, Yong-Beom Park1,2, Sang-Won Lee3,4.   

Abstract

OBJECTIVES: To investigate the detection rate of double positivity for antineutrophil cytoplasmic antibody (ANCA) and anti-glomerular basement membrane (GBM) antibody at diagnosis and its clinical implication during follow-up in Korean patients with ANCA-associated vasculitis (AAV).
METHODS: We retrospectively reviewed the medical records of 96 Korean AAV patients. We obtained data at diagnosis and assessed the poor outcomes of AAV such as all-cause mortality, relapse and end-stage renal disease (ESRD). Comparison of cumulative survivals were analysed by the Kaplan-Meier survival analysis, and hazard ratios (HRs) were obtained by the multivariable Cox hazard model.
RESULTS: Seven of 96 AAV patients (7.3%) had double positivity for ANCA and anti-GBM. Among variables at diagnosis, there were no significant differences between patients with double positivity for ANCA and anti-GBM and those without. In the cumulative survival analysis, AAV patient with double positivity for ANCA and anti-GBM at diagnosis exhibited the lower cumulative ESRD-free survival rate than those without (P = 0.044) and furthermore, than those with positive for only ANCA and those with double negativity (P = 0.022). Myeloperoxidase (MPO)-ANCA, renal manifestation and five-factor score at diagnosis were also associated with ESRD occurrence in AAV patients. In the multivariable Cox hazards model using these 4 variables, only double positivity for ANCA and anti-GBM exhibited the significant association with ESRD occurrence during follow-up (HR 3.831).
CONCLUSIONS: Double positivity for ANCA and anti-GBM at diagnosis were observed in 7.3% of AAV patients, and it could predict ESRD occurrence during follow-up in Korean patients with AAV.Key Points• 7.3% of AAV patients had double positivity for ANCA and anti-GBM at diagnosis (total n = 96)• Double positivity for ANCA and anti-GBM could predict ESRD occurrence during follow-up (HR 9.021, P = 0.004)• AAV patients with double positivity for ANCA and anti-GBM exhibited the lower cumulative ESRD-free survival rate compared with those without (P = 0.044).

Entities:  

Keywords:  Anti-glomerular basement membrane antibody; Antineutrophil cytoplasmic antibody; End-stage renal disease; Vasculitis

Mesh:

Substances:

Year:  2019        PMID: 31802348     DOI: 10.1007/s10067-019-04854-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

Review 1.  Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors:  C Mukhtyar; B Hellmich; D Jayne; O Flossmann; R Luqmani
Journal:  Clin Exp Rheumatol       Date:  2006 Nov-Dec       Impact factor: 4.473

2.  Risk Factors for Renal Survival in Chinese Patients with Myeloperoxidase-ANCA-Associated GN.

Authors:  Yinghua Chen; Hao Bao; Zhengzhao Liu; Xia Liu; Erzhi Gao; Caihong Zeng; Haitao Zhang; Zhihong Liu; Weixin Hu
Journal:  Clin J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 8.237

3.  Characteristics and outcome of crescentic glomerulonephritis in patients with both antineutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody.

Authors:  A Srivastava; G K Rao; P E Segal; M Shah; D Geetha
Journal:  Clin Rheumatol       Date:  2013-04-28       Impact factor: 2.980

4.  The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

Authors:  Loïc Guillevin; Christian Pagnoux; Raphaele Seror; Alfred Mahr; Luc Mouthon; Philippe Le Toumelin
Journal:  Medicine (Baltimore)       Date:  2011-01       Impact factor: 1.889

5.  Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease.

Authors:  Stephen W Olson; Charles B Arbogast; Thomas P Baker; David Owshalimpur; David K Oliver; Kevin C Abbott; Christina M Yuan
Journal:  J Am Soc Nephrol       Date:  2011-08-25       Impact factor: 10.121

6.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies.

Authors:  Richard Watts; Suzanne Lane; Thomas Hanslik; Thomas Hauser; Bernhard Hellmich; Wenche Koldingsnes; Alfred Mahr; Mårten Segelmark; Jan W Cohen-Tervaert; David Scott
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

Review 7.  Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis.

Authors:  Xavier Bossuyt; Jan-Willem Cohen Tervaert; Yoshihiro Arimura; Daniel Blockmans; Luis Felipe Flores-Suárez; Loïc Guillevin; Bernhard Hellmich; David Jayne; J Charles Jennette; Cees G M Kallenberg; Sergey Moiseev; Pavel Novikov; Antonella Radice; Judith Anne Savige; Renato Alberto Sinico; Ulrich Specks; Pieter van Paassen; Ming-Hui Zhao; Niels Rasmussen; Jan Damoiseaux; Elena Csernok
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

8.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Authors:  C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani
Journal:  Ann Rheum Dis       Date:  2008-12-03       Impact factor: 19.103

Review 9.  Current and emerging techniques for ANCA detection in vasculitis.

Authors:  Elena Csernok; Frank Moosig
Journal:  Nat Rev Rheumatol       Date:  2014-06-03       Impact factor: 20.543

10.  Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients.

Authors:  Stephen P McAdoo; Anisha Tanna; Zdenka Hrušková; Lisa Holm; Maria Weiner; Nishkantha Arulkumaran; Amy Kang; Veronika Satrapová; Jeremy Levy; Sophie Ohlsson; Vladimir Tesar; Mårten Segelmark; Charles D Pusey
Journal:  Kidney Int       Date:  2017-05-12       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.